Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 3‐4, by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants infectious at day 8 · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg may leads to lower participants infectious at day 3‐4 compared with no primaquine, with artemisinin partner, (low certainty).
2 findings from 1 review
Participants with gametocytes at day 3‐4, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with gametocytes at day 3 to 4 by PCR compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
Participants with severe haemolysis · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg showed no clear difference in participants with severe haemolysis compared with no primaquine, with artemisinin partner, (moderate certainty).
1 finding from 1 review
Seizure recurrence ‐ participants with a single cyst · people with neurocysticercosis
Albendazole probably leads to lower seizure recurrence ‐ participants with a single cyst compared with placebo or no anthelmintics (moderate certainty).
1 finding from 1 review
Intervention not reported
Attendance at single clinic appointment · People on TB treatment
The intervention may leads to higher attendance at single clinic appointment (low certainty).
1 finding from 1 review
Intervention not reported
Attendance at single clinic appointment · People on TB treatment
The intervention may leads to higher attendance at single clinic appointment (low certainty).
1 finding from 1 review
Parasitological failure At 2 years · patients with treating urinary schistosomiasis
It is very uncertain whether praziquantel 40 mg/kg multiple doses changes parasitological failure At 2 years compared with single dose (very low certainty).
1 finding from 1 review
Mean percent egg reduction At 2 years · patients with treating urinary schistosomiasis
1 finding from 1 review
Parasitological failure At 3 years · patients with treating urinary schistosomiasis
It is very uncertain whether praziquantel 40 mg/kg multiple doses changes parasitological failure At 3 years compared with single dose (very low certainty).
1 finding from 1 review
Adverse events: haematuria 12‐month · patients with treating urinary schistosomiasis
It is very uncertain whether praziquantel 40 mg/kg multiple doses changes haematuria At 3 years compared with single dose (very low certainty).
1 finding from 1 review
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
Intervention not reported
Treatment failure · treating pulmonary TB
The intervention showed no clear difference in treatment failure (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse · treating pulmonary TB
The intervention showed no clear difference in relapse (low certainty).
1 finding from 1 review
Intervention not reported
Death · treating pulmonary TB
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum smear or culture conversion at end of treatment · treating pulmonary TB
The intervention showed no clear difference in sputum smear or culture conversion at end of treatment (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review